Sign in
Stories
FDA Clearance for NOX-A12 Phase 2 Trial
Share
Advancements in Brain Cancer, TTFields, ...
Advancements in Cancer Treatment and Mar...
Advancements in Clinical Trials
AI-Powered Cancer Drug Trials
Advancing CD70 Targeted Cancer Treatment...
Affini-T Therapeutics at J.P. Morgan Hea...
Overview
API
TME Pharma gains FDA approval for NOX-A12 Phase 2 trial targeting glioblastoma, aiming to showcase efficacy in 100 patients alongside bevacizumab.
Ask a question
How could the success of NOX-A12 impact the broader landscape of brain cancer therapeutics?
How might the Phase 2 trial results influence the future of glioblastoma treatment?
What challenges could TME Pharma face in the US market expansion for NOX-A12?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Dec 2023
Jan 2024
Feb 2024
Coverage